07:41 AM EDT, 07/15/2025 (MT Newswires) -- Acumen Pharmaceuticals ( ABOS ) has entered into a collaboration, option and license agreement with JCR Pharmaceuticals to develop an oligomer-targeted enhanced brain delivery therapy for Alzheimer's disease, the companies said Tuesday.

Under the terms of the deal, JCR will receive an upfront payment and will be eligible for an additional option payment in case Acumen decides to exercise its exclusive option to develop up to two development candidates.

JCR separately said it will also be eligible to receive future milestone payments of up to $40 million related to development, and up to $515 million related to sales. The company is also entitled to receive tiered royalties based on net sales for any products that emerge from the collaboration.

Acumen shares were down 6% in recent premarket activity.